Drug Trial Radar · NCT00140049
A 12week, Randomized, Evaluator-Masked, Parallel Group Comparing Evening Dosing Of Xalacom Vs Cosopt In Subj W/ Glaucoma
Last checked: Nov 20, 2026Latest source record: Feb 18, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
238
Actual
Start
Jul 2005
Primary completion
Not stated
Study completion Jul 2006
Sponsor
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Pfizer (PFE)
- Sponsor type
- Industry
- First posted
- Aug 31, 2005
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To demonstrate the statistical non inferiority of the combination of latanoprost and timolol given in the evening time once a day vs the combination of dorzamalide and timolol twice a day based on intraocular pressure measurements at 8 AM, 12 noon \& 4 PM during a 12 week treatment.
Conditions
- Glaucoma, Open Angle
- Ocular Hypertension
Interventions
XalacomDrug
CosoptDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- The mean IOP measurements obtained in the study eye at each time point
Locations
25 sites in 5 countries. Site status is shown where the registry gives one.
Pfizer Investigational Site
Caen, France
Pfizer Investigational Site
Clermont-Ferrand, France
Pfizer Investigational Site
Lyon, France
Pfizer Investigational Site
Marseille, France
Pfizer Investigational Site
Saint-Herblain, France
Pfizer Investigational Site
Darmstadt, Germany
Pfizer Investigational Site
Darmstadt, Germany
Pfizer Investigational Site
Landau / Pfalz, Germany
Pfizer Investigational Site
Regenstauf, Germany
Pfizer Investigational Site
Schorndorf, Germany
Pfizer Investigational Site
Starnberg, Germany
Pfizer Investigational Site
Alexandroupoli, Greece
Pfizer Investigational Site
Larissa, Greece
Pfizer Investigational Site
Heraklion, Crete, Greece
Pfizer Investigational Site
Thessaloniki, Macedonia, Greece
Pfizer Investigational Site
Chieti, Italy
Pfizer Investigational Site
Foggia, Italy
Pfizer Investigational Site
Genova, Italy
Pfizer Investigational Site
Milan, Italy
Pfizer Investigational Site
Monza (MI), Italy
Pfizer Investigational Site
Pisa, Italy
Pfizer Investigational Site
örebro, Sweden
Pfizer Investigational Site
Malmö, Sweden
Pfizer Investigational Site
Mölndal, Sweden
Pfizer Investigational Site
Sundsvall, Sweden
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.